SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is actively discussed following a strong earnings beat, healthy guidance, and the announcement of a $500 million stock repurchase program, which surprisingly saw the stock decline and fuel community speculation about market manipulation, short squeeze potential, and competition in the evolving AI automation sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

High anticipation surrounds POET Technologies ahead of the OFC Conference, where it will showcase advanced AI optical engines, and community excitement intensifies over its perceived connection to Marvell Technology's strong guidance for Celestial AI's photonic fabric. Investors are actively discussing potential partnership announcements and a production ramp-up, underscoring the company's position in the rapidly expanding AI optical interconnect market.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. (SOC) is trending as the community anticipates a significant short squeeze following reports that President Trump may invoke the Defense Production Act to bypass California's regulatory obstacles, potentially enabling the restart of its idle Santa Ynez oil operations amidst a tightening global crude supply. Investors are closely watching for an acceleration of oil production and the market impact on highly shorted shares.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is gaining significant attention following its new SiC MOSFET package releases, specifically designed for high-density AI data centers and power infrastructure, which reinforces its strategic pivot to high-growth markets highlighted in its Q4 update. The community is actively discussing the company's critical role in addressing AI's power efficiency needs, eagerly awaiting major design wins and updates on collaborations with hyperscalers like NVIDIA.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amidst widespread investor frustration over its persistent stock decline, primarily driven by founder Chip Wilson's public campaign challenging the board's weak governance and strategic drift, compounded by recent brand scrutiny over a "too sheer" product launch and ongoing uncertainty surrounding executive leadership. The community is actively debating whether the current low valuation represents a buying opportunity or reflects deeper issues exacerbated by perceived market manipulation.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Papa John's is trending following reports of a $47-per-share takeover bid by Qatari-backed Irth Capital, fueling community speculation on whether the board will accept, the potential for higher offers, and its overall valuation compared to past highs.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is a major talking point following its recent Q4 earnings report and FY27 guidance, which showcased robust ARR growth and a milestone first year of positive free cash flow, despite community concerns over a large impending share lock-up expiration. Investors are actively weighing short-term dilution against the company's long-term potential as a leader in AI-native cybersecurity and the expanding SASE market.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMC Robotics (AMCI) is trending due to recent announcements surrounding its NovaArm and Kyro robotics platforms, including a Vietnam manufacturing hub and a Japanese government supplier framework, positioning it as a key player in AI-enabled robotics. While many foresee significant growth and potential short squeezes, others remain cautious of low trading volume, past dilution, and alleged price manipulation, despite its presence in a high-interest tech sector.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Xanadu Quantum Technologies, merging with CHAC, is generating significant buzz after announcing negotiations for up to CAD $390 million in government support from Canada and Ontario, alongside recent collaborations with AMD and South Korea's ETRI. The community sees these developments as strong validation of its photonic quantum computing approach, positioning it as a leading contender in bringing quantum technology to real-world applications ahead of its impending public listing.

Caesars Entertainment, Inc. engages in the management of casinos and resorts under the Caesars, Harrah's, Horseshoe, and Eldorado brands. It operates through the following segments: Las Vegas, Regional, Caesars Digital, Managed and Branded, and Corporate and Other. The company was founded in 1937 and is headquartered in Reno, NV.

Caesars Entertainment Inc

Caesars Entertainment (CZR) is surging on news that billionaire Tilman Fertitta is in exclusive talks to acquire the company for an estimated $34 per share, topping a prior bid from Carl Icahn's firm. This potential deal has ignited community debate, with many shareholders expressing disappointment over the perceived low valuation relative to past highs, while others speculate on a possible bidding war amidst the company's significant debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evoke Pharma and QOL Medical Announce Expiration of Tender Offer

Evoke Pharma and QOL Medical Announce Expiration of Tender Offer Evoke Pharma and QOL Medical Announce Expiration of Tender Offer PR Newswire SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025...

Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN...

<ul class="summary-bullets"><li>QOL Medical will buy Evoke for $11 per share, representing a premium of about 140% from the stock’s closing price on Monday.&nbsp;</li><li>The transaction has been approved by the boards of both companies and is expected to close by the end of 2025.</li><li>QOL Medical intends to finance the transaction with cash on hand. &nbsp;</li></ul>Shares of Evoke Pharma, Inc. (EVOK) more than doubled on Tuesday after the company said that it has entered into a definitive agreement to be acquired by privately-held QOL Medical for $11 per share.The purchase price represents a premium of about 140% from the stock’s closing price on Monday.Following the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/04/3180135/28255/en/Evoke-Pharma-Enters-into-Definitive-Agreement-to-Be-Acquired-by-QOL-Medical.html">announcement</a>, <a href="https://stocktwits.com/symbol/EVOK">EVOK shares</a> shot up 134% by Tuesday afternoon to hit $10.72 as of the time of writing, but still remained below the deal price.<h2 class="st-heading-2">Terms Of The Deal</h2>Florida-based QOL Medical will initiate a tender offer to acquire all outstanding shares of Evoke through a subsidiary. Once the tender offer is completed, a unit of QOL Medical will merge with Evoke.&nbsp;The transaction has been approved by the boards of both companies and is expected to close by the end of 2025. QOL Medical intends to finance the transaction with cash on hand.Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a chronic condition where the stomach takes too long to empty due to nerve damage caused by poorly controlled diabetes. Symptoms include nausea, vomiting, and bloating, among others.The gastric delay caused by gastroparesis can compromise absorption of orally administered medications, and until approval of Gimoti, treatment was available only in oral and injectable formulations.“GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions,” QOL Medical CEO Derick Cooper said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EVOK jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/59;" src="data:image/png;base64,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" width="621" height="59" alt="EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the stockholders.<stembedurl>https://stocktwits.com/erb71/message/634823600</stembedurl>EVOK stock is up by 143% this year and by 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

Equity

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc...

EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fair to Evoke shareholders...

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend the market life of Gimoti, its nasal spray treatment for gastroparesis.The patent, once issued, would provide Evoke with added protection through December 2036, covering the use of the drug in patients with moderate to severe symptoms of the condition.&nbsp;Gastroparesis impairs the stomach’s ability to empty, often rendering oral medications less effective.&nbsp;Evoke plans to list the new patent in the FDA’s Orange Book, which would extend exclusivity for Gimoti beyond its current timeline.The news comes alongside improving financials. In the first quarter of 2025, Evoke generated approximately $3.1 million in product sales, nearly doubling its revenue from the same period a year earlier.&nbsp;The company reported a net loss of $1.3 million, which&nbsp;translates to a loss of $0.51 per share, representing an improvement from the $1.6 million loss, or $2.09 loss per share, in the same quarter last year.Spending also ticked up, driven mainly by higher fees and profit-sharing with Eversana, its commercial partner.&nbsp;Operating expenses totaled $4.4 million, up from $3.2 million a year earlier.As of March 31, Evoke had $12.6 million in cash.&nbsp;Based on its current plans, it expects to carry operations into the second quarter of 2026.&nbsp;The company is also sticking to its 2025 sales goal of $16 million, which would be a 60% increase from last year if current trends continue.On Stocktwits, retail sentiment for Evoke was ‘extremely bullish’ amid ‘extremely high’ message volume.One user mentioned buying 100 lots of Evoke’s stock and said they were waiting for a potential move to cover.&nbsp;<stembedurl>https://stocktwits.com/mikefromclt/message/620413256</stembedurl>Another user expressed a bullish outlook as well, saying they were fully loaded on the stock and planned to hold their position into the next session.<stembedurl>https://stocktwits.com/stocksweets/message/620411085</stembedurl><a href="https://stocktwits.com/symbol/EVOK">Evoke’s stock</a> has risen 56.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Evoke Pharma (EVOK) received a new U.S. patent that could extend the market life of Gimoti/ Photo credit: Getty Images

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 

Evoke shares drop 15% as loss widens despite revenue growth

Evoke expects earnings to exceed market expectations, shares jump

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

EVOK
Evoke Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EVOK News

EVOKEvoke Pharma Inc